ASMB — Assembly Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $439.40m
- $191.29m
- $72.30m
Annual cashflow statement for Assembly Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -130 | -93.1 | -61.2 | -40.2 | -6.12 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 49.9 | 10.3 | 7.18 | 0.879 | 3.18 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -11.4 | -2.12 | 76.3 | -11.9 | -38.3 |
| Change in Accounts Receivable | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -93.4 | -84.5 | 22.7 | -51.1 | -41.1 |
| Capital Expenditures | -3.1 | -0.102 | -0.255 | -0.028 | -0.066 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 29.6 | 90.7 | -68.9 | 40.2 | -113 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 26.5 | 90.6 | -69.1 | 40.2 | -113 |
| Financing Cash Flow Items | 0.258 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 53.1 | 0.614 | 13.8 | 29.4 | 175 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -13.8 | 6.79 | -32.6 | 18.5 | 20.1 |